CV Therapeutic Inc.’s Ranexa™ is now available in pharmacies and is now being promoted to cardiology specialists in the United States. Ranexa™ (ranolazine extended-release tablets) is approved as second-line treatment for chronic angina and has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure.
Ranexa™ is the first new pharmaceutical treatment for chronic angina in more than 20 years. Thus, its availability in the market has long been awaited by angina patients and their families, including the entire cardiology community. This is definitely good news because some 6.5 million people in the
Source: CVT Press Release
» CV Therapeutics’ MERLIN TIMI-36 Study, Granted DSMB Go Signal to Proceed as Planned from ThePharmVoice
CV Therapeutics, Inc.’s MERLIN TIMI-36 study of Ranexa® (ranolazine extended-release tablets), has been given the go signal by the Data Safety Monitoring Board (DSMB) (the study’s overseer) to go ahead as planned. MERLIN TIMI-36 (Metabo... [Read More]
Tracked on: July 11, 2006 3:36 AM | Permalink to Trackback